Top Page
Next Science Ltd
(Sydney:NXS)
Next Science Ltd (NXS) vs. iShares MSCI Australia ETF (EWA)
Next Science Ltd Business Overview & Revenue Model
Next Science Ltd Earnings Call Summary
Next Science Ltd Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.82M | 22.18M | 16.90M | ― | ― |
| Gross Profit | 18.44M | 16.23M | 11.90M | ― | ― |
| EBITDA | -9.03M | -14.42M | -17.02M | ― | -13.18M |
| Net Income | -10.59M | -24.51M | -18.30M | ― | -13.27M |
Balance Sheet | |||||
| Total Assets | 9.21M | 17.90M | 18.37M | 13.67M | 23.49M |
| Cash, Cash Equivalents and Short-Term Investments | 1.67M | 9.28M | 7.54M | ― | 15.24M |
| Total Debt | 2.49M | 961.97K | 1.80M | ― | ― |
| Total Liabilities | 5.77M | 5.08M | 6.52M | ― | ― |
| Stockholders Equity | 3.44M | 12.82M | 11.85M | 10.73M | 18.80M |
Cash Flow | |||||
| Free Cash Flow | -8.55M | -15.94M | -17.69M | ― | -14.03M |
| Operating Cash Flow | -7.96M | -15.06M | -17.01M | ― | -13.26M |
| Investing Cash Flow | -589.22K | -884.50K | -686.23K | ― | ― |
| Financing Cash Flow | 1.75M | 20.11M | 14.78M | ― | 11.93M |
Next Science Ltd Technical Analysis
Next Science Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$45.03M | 20.00 | 4.85% | ― | 5.76% | -79.76% | |
53 Neutral | AU$24.68M | ― | -218.38% | ― | -14.30% | 29.69% | |
52 Neutral | $7.36B | -0.07 | -63.77% | 2.36% | 16.35% | 0.03% | |
47 Neutral | AU$40.97M | ― | -130.18% | ― | 3.37% | 47.32% | |
46 Neutral | AU$40.03M | ― | -19.31% | ― | 72.25% | 43.66% | |
41 Neutral | AU$73.79M | ― | -45.40% | ― | 13.61% | -55.12% |
Next Science Ltd Corporate Events
Next Science Limited announced a change in the director’s interest, with Managing Director Harry Thomas Hall, IV acquiring 465,131 ordinary fully paid shares as part of an equity settlement. This change reflects the issuance of new shares in settlement of tranche 2 of the Sign-On Rights, approved by shareholders at the company’s 2024 AGM, indicating a strategic move to align executive interests with company performance.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
Next Science Ltd has issued 465,131 ordinary shares to its Managing Director and CEO, I.V. Hall, as part of the settlement for tranche 2 of the Sign-On Rights. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant legal provisions, indicating a transparent and regulated approach to executive compensation.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
Next Science Limited announced that all resolutions were passed at its 2025 Annual General Meeting, as determined by a poll. This successful meeting outcome reflects positively on the company’s governance and may reinforce stakeholder confidence, potentially impacting its market positioning favorably.
Next Science Limited held its 2025 Annual General Meeting, where the Chair and CEO highlighted significant operational improvements and strategic advancements made in 2024. The company reduced its cash burn by US$7 million, improved margins, and achieved cash flow positivity for two non-consecutive months. With a US$5 million loan facility secured, Next Science is well-positioned for future growth. Clinical research published in 2024 demonstrated the effectiveness of its products, BLASTX and XPERIENCE, in reducing infections and inflammation, contributing to lower healthcare costs. The company also continued its large-scale study on periprosthetic joint infections, enrolling 1,220 patients by the end of 2024. Despite a decline in the Durable Medical Equipment channel, Next Science achieved record revenue of US$22.8 million, driven by strong direct and partner sales.
Next Science Limited announced that a derivative complaint filed by Michael Morello in Florida’s Duval County Court has been dismissed due to lack of standing. However, the litigation initiated by Next Science LLC against Mr. Morello and other former employees for breach of post-employment restraints is still ongoing, indicating continued legal proceedings that may impact the company’s operations and stakeholder interests.
Next Science Ltd announced the cessation of 250,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence investor perceptions, although the specific implications for stakeholders were not detailed in the release.
Next Science Limited reported a slight decline in product sales for the first quarter of FY25, with total sales of US$5.3 million, a 3% decrease from the prior corresponding period. Despite a significant increase in direct sales of XPERIENCE and BLASTX products, the overall sales were impacted by a decline in Durable Medical Equipment (DME) sales. The company maintained a strong gross margin of 84%, attributed to a favorable product mix. Additionally, Next Science addressed an FDA Warning Letter, ensuring that their products remain safe and effective for their intended uses, and continued to focus on achieving a positive cash flow position.